As shown in Figure 3, serum visfatin cutoff value ≥ 9.06 ng/ml can be used as a cutoff point at which 80% of breast cancer patients (T1 and T2 stages) can be early diagnosed correctly but 14.71% of normal subjects are false positive. The gene discussed is NAMPT; the disease is breast carcinoma.